DVAX - Dynavax Technologies Corp.
IEX Last Trade
11.21
-0.050 -0.446%
Share volume: 1,090,588
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$11.26
-0.05
-0.44%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-04 | 2022-11-03 | 2023-02-23 | 2023-05-02 | 2023-08-03 | 2023-11-02 | 2024-02-22 | 2024-05-08 | |
Assets | |||||||||
Total Assets | 1.023 B | 999.337 M | 985.850 M | 969.922 M | 936.432 M | 972.933 M | 997.096 M | 986.565 M | |
Current Assets | 955.405 M | 932.944 M | 916.985 M | 830.141 M | 797.460 M | 835.666 M | 859.120 M | 851.286 M | |
Inventories | 73.979 M | 102.609 M | 59.446 M | 57.693 M | 53.088 M | 49.412 M | 53.290 M | 61.806 M | |
Other Current Assets | 189.015 M | 112.731 M | 85.629 M | 15.626 M | 17.494 M | 18.972 M | 18.995 M | 19.788 M | |
Short Term Investments | 189.015 M | 112.731 M | 85.629 M | 15.626 M | 17.494 M | 18.972 M | 18.995 M | 19.788 M | |
Total Receivables | 174.242 M | 131.118 M | 147.515 M | 104.866 M | 45.353 M | 46.866 M | 44.533 M | 46.154 M | |
Current Cash | 518.169 M | 586.486 M | 624.395 M | 651.956 M | 681.525 M | 720.416 M | 742.302 M | 723.538 M | |
Total Non-current Assets | 67.594 M | 66.393 M | 68.865 M | 139.781 M | 138.972 M | 137.267 M | 137.976 M | 135.279 M | |
Property Plant Equipment | 36.286 M | 35.352 M | 37.596 M | 38.159 M | 37.442 M | 36.183 M | 37.297 M | 36.413 M | |
Other Assets | 3.363 M | 3.337 M | 3.311 M | 73.941 M | 73.915 M | 74.154 M | 74.325 M | 73.452 M | |
Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Goodwill | 1.958 M | 1.835 M | 2.006 M | 2.038 M | 2.039 M | 1.981 M | 2.067 M | 2.022 M | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 1.023 B | 999.337 M | 985.850 M | 969.922 M | 936.432 M | 972.933 M | 997.096 M | 986.565 M | |
Total liabilities | 600.200 M | 498.761 M | 404.837 M | 406.190 M | 359.227 M | 368.017 M | 375.024 M | 368.085 M | |
Total current liabilities | 345.198 M | 244.080 M | 150.074 M | 91.515 M | 44.862 M | 54.264 M | 62.195 M | 56.002 M | |
Accounts Payable | 4.959 M | 3.050 M | 3.211 M | 7.296 M | 3.246 M | 3.120 M | 5.245 M | 2.431 M | |
Other liabilities | 295.000 K | 251.000 K | 384.000 K | 60.689 M | 60.686 M | 60.658 M | 60.411 M | 60.540 M | |
Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Long term debt | 221.030 M | 221.303 M | 221.578 M | 221.855 M | 222.134 M | 222.415 M | 222.698 M | 222.984 M | |
Other liabilities | 295.000 K | 251.000 K | 384.000 K | 60.689 M | 60.686 M | 60.658 M | 60.411 M | 60.540 M | |
Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Total Shareholder equity | 422.799 M | 500.576 M | 581.013 M | 563.732 M | 577.205 M | 604.916 M | 622.072 M | 618.480 M | |
Common stock | 126.347 M | 127.062 M | 127.628 M | 127.921 M | 128.625 M | 128.988 M | 129.398 M | 130.200 M | |
Retained earnings | -1.056 B | -991.928 M | -924.195 M | -948.527 M | -945.096 M | -930.803 M | -930.584 M | -939.305 M |